LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

CareDx to Participate in Upcoming Investor Conferences

May 29, 2024 | Last Trade: US$17.72 0.44 2.55

BRISBANE, Calif. / May 29, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.

CareDx’s management is scheduled to present at the:

  • Jefferies Global Healthcare Conference on Thursday, June 6, 2023, at 11:30 AM PT / 2:30 PM ET.
  • Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2023, at 1:00 PM PT / 4:00 PM ET.

To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page